Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026

Champions Oncology plans to release July 31, 2026 quarter results and hold an investor conference call with replay access on September 10, 2026.

Rhea-AI Summary

Champions Oncology (CSBR) will report financial and operational results for the quarter ended July 31, 2026 on Thursday, September 10, 2026, after market close.

The company will host a conference call at 4:30 P.M. EDT (1:30 P.M. PDT). Participants can join via domestic dial-in 888-506-0062 or international 973-528-0011 using access code 938837. A replay will be available by phone and via the investors section of the company website.

Market Context

The July 20 earnings-date notice was followed by a 0% 24-hour move, while CSBR's pre-headline close ...

Analysis

The July 20 earnings-date notice was followed by a 0% 24-hour move, while CSBR's pre-headline close was $5.28. This update adds scheduling information only; the forthcoming results remain the central uncertainty.

Key Figures

Quarter End: July 31, 2026 Results Announcement: September 10, 2026

2 metrics

Quarter End July 31, 2026 First quarter

Results Announcement September 10, 2026 After market close

Previous Earnings date Reports

3 past events · Latest: Jul 20 (Neutral)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 20	Fourth-quarter earnings date	Neutral	+0.0%	Scheduled fourth-quarter and year-end results after market close
Mar 05	Third-quarter earnings date	Neutral	+2.4%	Scheduled third-quarter results and conference call after market close
Dec 08	Second-quarter earnings date	Neutral	+0.2%	Scheduled second-quarter financial and operational results after market close

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings-date notices produced two positive moves and one flat move, with an average move of 0.87%.

Key Terms

patient-derived xenograft, in vivo, ex vivo

3 terms

patient-derived xenograft medical

"bank of clinically relevant patient-derived xenograft (PDX) and primary hematological"

A patient-derived xenograft (PDX) is a laboratory model created by implanting a tumor or diseased tissue taken directly from a human patient into an animal host that can support its growth. Because PDX models tend to mirror how a human tumor behaves and responds to treatments better than simple cell cultures, investors view their use as a stronger signal that preclinical drug results may translate to patients, lowering development risk much like a full-scale dress rehearsal raises confidence before opening night.

in vivo technical

"longitudinal in vivo imaging of radiopharmaceutical uptake"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

ex vivo technical

"proprietary in vivo and ex vivo platforms"

Ex vivo describes tests or treatments performed on living cells, tissues, or organs that have been removed from the body and studied in an external environment. For investors, ex vivo work sits between basic lab dish tests and whole‑animal or human studies, offering a more realistic preview of how a therapy or diagnostic might behave in real tissue — like running an engine on a test stand before putting it back into a car — which can reduce scientific risk and inform development milestones.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / Champions Oncology, Inc. (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 938837. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 54523, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions and innovative data platforms to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

Media Inquiries:

Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com

Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/

SOURCE: Champions Oncology, Inc.

View the original press release on ACCESS Newswire

FAQ

When will Champions Oncology (CSBR) report its first quarter 2026 financial results?

Champions Oncology (CSBR) will report its financial and operational results for the quarter ended July 31, 2026 on Thursday, September 10, 2026, after market close. The release will be followed by a conference call that same day.

What time is the Champions Oncology (CSBR) earnings conference call on September 10, 2026?

The Champions Oncology (CSBR) earnings conference call is scheduled for 4:30 P.M. EDT (1:30 P.M. PDT) on September 10, 2026, to discuss financial and operational results for the quarter ended July 31, 2026.

How can investors join the Champions Oncology (CSBR) Q1 2026 earnings call?

Investors can join the Champions Oncology (CSBR) call by dialing 888-506-0062 (Domestic) or 973-528-0011 (International) and entering access code 938837. The call is on September 10, 2026, at 4:30 P.M. EDT.

Is there a replay available for the Champions Oncology (CSBR) September 10, 2026 earnings call?

Yes. A replay is available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode 54523. A replay can also be accessed via the investors section of the company’s website within 72 hours.